Document is current
Any future updates will be listed below
-
Authors
Sarter, H.
Kirschgesner, J.
Beaugerie, L.
Buisson, A.
Gower-Rousseau, C.
de Pouvourville, Gérard https://orcid.org/0000-0002-5941-6823
-
Funding
Funding for this research was provided by:
Amgen France (Amgen France)
Biogaran (Biogaran)
Janssen Research and Development (Janssen Research and Development)
Merck Sharp and Dohme France (Merck Sharp and Dohme France)
EuroQol Research Foundation (EuroQol Research Foundation)
- License Information
-
More Information
Article History
Accepted: 21 October 2024
First Online: 29 October 2024
Declarations
:
: This study has received a registration of compliance to MR3 reference methodology (n° 2200570 v 0). Research methodology MR3 does not require informed consent to participate, since the research was not interventional. But all respondents were given a letter of information on their rights to access to their personal data and to retrieve them. It has received an approval form the Personal Protection Committee (CPP) on November 20, 2018, under the registration number ID-RCB 2018-A02189-46. The study is registered at the National Drugs Agency (ANSM) under the preceding number.
: See preceding statement.
: Funding was made to institutions. None of the authors received personal funding for the research.
